New Horizons in the Management of Hereditary Angioedema (HAE):
What Managed Care Needs to Know About Novel Therapies in an
Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN

New Horizons in the Management of Hereditary Angioedema (HAE): What Managed Care Needs to Know About Novel Therapies in an Evolving Treatment Paradigm is a 3-part webcast series that will provide attendees with the latest information in the management of Hereditary Angioedema.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These are archives of live webinars held between February 13, 2019 to February 20, 2019.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

This series is supported by an educational grant from CSL Behring

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  

Description:

Hereditary angioedema (HAE) is a rare autosomal dominant condition characterized by recurrent attacks of edema at different locations of the body. This potentially life-threatening disease affects approximately 1 in 67,000 individuals. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected. Fortunately, novel therapies have recently become available that have shown improved efficacy and safety with improved administration methods. 

 This webinar series will feature strategies to overcome challenges in the optimal long-term treatment of HAE, updates on new therapies, and practical managed care approaches to provide cost-effective solutions to improve patient outcomes. 


Part 1
A Deeper Look into the Newest Therapies in the Management of Hereditary Angioedema (HAE): Individualizing Treatment for Improved Clinical and Economic Outcomes

  • Describe the pathophysiology, etiology and challenges preventing the early diagnosis of hereditary angioedema (HAE)

  • Explore ways to identify patients with HAE earlier by utilizing appropriate testing consistently for optimal diagnosis

  • Analyze safety and efficacy data of recently approved therapies for the prophylaxis of HAE

  • Discuss individualized HAE treatment strategies, taking into consideration risks and benefits of therapies, disease characteristics and severity, comorbid conditions, patient quality of life, and patient preference
    Physician, Nursing and CMCN credits valid to March 1, 2020
     

Part 2
Improving Patient Adherence and Quality of Life in Hereditary Angioedema (HAE): Strategies for Improving Administration of Treatment and Managing Adverse Events

  • Examine novel administration methods for novel therapies in Hereditary Angioedema (HAE) and how they are changing the treatment paradigm

  • Identify strategies for anticipating, recognizing, and managing adverse events of novel therapy in patients with HAE

  • Discuss methods to communicate effectively with HAE patients and the multidisciplinary team to understand and address the needs of each patient around C1 Esterase Inhibitors and improve treatment adherence and quality of life

  • Review how treatment strategies can be affected by adverse events based on patientís individualized needs
    Physician
    , Nursing and CMCN credits valid to March 1, 2020
     

Part 3
Comparative Effectiveness and Coordinated Care in Hereditary Angioedema (HAE): What Does Managed Care Need to Know about Recently Approved Therapies?

  • Identify key economic challenges surrounding management of patients with hereditary angioedema (HAE) and the need for more optimal medical intervention to reduce healthcare costs

  • Analyze safety and efficacy data of recently approved therapies for the prophylaxis of HAE

  • Apply methods to enable optimal cost management of novel therapies to be realized by multiple HAE stakeholders including managed care organizations
    Physician, Nursing and CMCN credits valid to March 1, 2020